key: cord-0799432-o1ky8tyv authors: Saha, Senjuti; Malaker, Roly; Sajib, Mohammad Saiful Islam; Hasanuzzaman, Md; Rahman, Hafizur; Ahmed, Zabed B.; Islam, Mohammad Shahidul; Islam, Maksuda; Hooda, Yogesh; Ahyong, Vida; Vanaerschot, Manu; Batson, Joshua; Hao, Samantha; Kamm, Jack; Kistler, Amy; Tato, Cristina M.; DeRisi, Joseph L.; Saha, Samir K. title: Complete Genome Sequence of a Novel Coronavirus (SARS-CoV-2) Isolate from Bangladesh date: 2020-06-11 journal: Microbiol Resour Announc DOI: 10.1128/mra.00568-20 sha: e0cb60b21b17bcc51bfcf5af0b81cd60bed047cd doc_id: 799432 cord_uid: o1ky8tyv The complete genome sequence of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) isolate obtained from a nasopharyngeal swab from a patient with COVID-19 in Bangladesh is reported. C oronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family Coronaviridae and the genus Betacoronavirus. In Bangladesh, the first three cases were detected on 8 March 2020. By 14 May 2020, more than 18,000 cases and 280 deaths had been reported in the country. The Child Health Research Foundation (CHRF) has been a testing center for COVID-19 since 29 March 2020 and uses quantitative PCR (qPCR)based SARS-CoV-2 detection in nasopharyngeal or oropharyngeal swab samples (1) . Here, we report the complete sequence of a SARS-CoV-2 isolate from a patient who tested positive in a qPCR test. All protocols were approved by the National Research Ethics Committee, Bangladesh Medical Research Council, and the ethical review board of the Bangladesh Institute of Child Health. Samples from suspected COVID-19 patients were collected for clinical care and diagnostic testing at the discretion of the attending health care providers and were received and tested at the CHRF with the permission of the Director General Health Services, Government of Bangladesh. For this study, a nasopharyngeal specimen from a symptomatic patient with COVID-19 was collected on 18 April 2020. The specimen was tested for SARS-CoV-2 using qPCR at the CHRF and had a low cycle threshold value (C T Ͻ 15). Extraction of the viral nucleic acid from the nasopharyngeal specimen was performed using the Quick-RNA/DNA microprep extraction kit (product no. D7005; Zymo) according to the manufacturer's protocol. cDNA was converted to Illumina libraries using the NEBNext Ultra II RNA library preparation kit (product no. E7770; NEB) according to the manufacturer's protocol. Targeted enrichment of the SARS-CoV-2 sequence using 73 tiling primers at a 20:1 molar ratio of random primers to tiled primers was adapted from viral genome recovery methods described previously (2, 3) . External RNA Controls Consortium Collection spike-in control mix (product no. 4456740; Thermo Fisher Scientific) was used as a marker of potential library preparation errors and for input RNA mass calculation. The library was sequenced on an Illumina iSeq100 sequencer using 150-nucleotide pairedend sequencing present at CHRF. The library generated 15,376,000 reads, of which 11,747,398 passed the default Illumina quality filter in BaseSpace. Raw fastq files were uploaded to the IDSeq portal for host subtraction (4). SARS-CoV-2 reads were recovered by mapping the raw reads against the reference sequence (GenBank accession no. MN908947.3) using minimap2 (v2.17) (5, 6) and filtering the reads that mapped against a database of human and other viral genomes using Kraken2 (v2.0.8_beta) (7) . The surviving reads were adapter trimmed with Trim Galore and remapped to the same reference using minimap2. Enrichment primers were trimmed with iVar (v1.2), and the consensus genome was called using iVar (8, 9) . The full pipeline is available online (https://github.com/ czbiohub/sc2-msspe-bioinfo). The complete genome of the Bangladeshi SARS-CoV-2 strain (CHRF_nCoV19_0001) has 29,903 bp, with an average coverage of over 3,000ϫ; no indels were detected, and the GC content was 38%. The sample was uploaded to the Global Initiative on Sharing All Influenza Data (GISAID) database (10) on 12 May 2020. The genome was subsequently contextualized among 5,265 other genomes available in the GISAID database in the Nextstrain Asia build of 15 May 2020 (www.nextstrain.org/ncov/asia) (11) . Phylogenetic analysis of this virus genome showed that it was grouped in SARS-CoV-2 clade A2a. The genome contained two mutations not observed in the closest previously observed genotype, which occurred in samples from Ireland, Italy, Greece, Hungary, the Czech Republic, Denmark, the United States, Turkey, Jordan, Russia, Georgia, Vietnam, Argentina, Switzerland, Spain, New Zealand, India, Taiwan, Singapore, and Japan (Fig. 1) . Because of the wide geographic spread of that closest ancestral genotype, it is difficult to infer the specific route by which the strain came to Bangladesh. As more SARS-CoV-2 genomes from Bangladesh and around the world are sequenced, we will be able to better monitor new introductions into and transmission dynamics within Bangladesh. In total, 9 mutations were observed in CHRF_nCoV19_0001, compared to the reference genome for the Wuhan strain (GenBank accession no. MN908947.3) from December 2019 (Table 1) . These mutations included the spike protein D614G mutation that is enriched in recent SARS-CoV-2 isolates, especially from Europe and North America (12) . Other mutations of interest included the position 28881 to 28883 GGG¡AAC mutation, which changes the sequence of nucleoprotein N at positions 203 and 204 from RG to KR. In the Nextstrain global build of 15 May 2020, this mutation is predicted to have emerged at the end of January 2020 and is present in many isolates from clade A2a (11) . Finally, one mutation observed is unique to CHRF_nCoV19_0001, i.e., A1163T. This mutation leads to a I300F change in open reading frame 1a (ORF1a) (on the nsp2 protein), and its prevalence in Bangladesh should be monitored closely. We are currently sequencing more genomes from different regions of Bangladesh and from patients with different clinical features to further investigate the spread of COVID-19 and to monitor the evolution of SARS-CoV-2 in Bangladesh. Data availability. The SARS-CoV-2 genome from Bangladesh was deposited in the GISAID database (accession no. EPI_ISL_437912) and GenBank (accession no. MT476385). The raw reads have been deposited in the NCBI Sequence Read Archive (SRA accession no. SRR11801823). The BioProject and BioSample accession no. are PRJNA633241 and SAMN14938301, respectively. Molecular assays to diagnose COVID-19: summary table of available protocols Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance Rapid metagenomic characterization of a case of imported COVID-19 in Cambodia IDseq: an open source cloud-based pipeline and analysis service for metagenomic pathogen detection and monitoring A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data minimap2: pairwise alignment for nucleotide sequences Improved metagenomic analysis with Kraken 2 An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar Cutadapt removes adapter sequences from highthroughput sequencing reads. 1 GISAID: Global Initiative on Sharing All Influenza Data: from vision to reality Nextstrain: real-time tracking of pathogen evolution Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 We thank the Director General Health Services, Government of Bangladesh, and the Institute of Epidemiology, Disease Control, and Research for giving us the opportunity to work as a COVID-19 response team. We thank the health facilities in Bangladesh that sent us samples for COVID-19 testing and all personnel at CHRF for their work at the COVID-19 diagnostic center, and we thank the Chan Zuckerberg Biohub and the Chan Zuckerberg Initiative for their intellectual support and guidance.We received funding from the Bill and Melinda Gates Foundation (grant INV-016932) for this project.